Atossa Therapeutics/$ATOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Ticker
$ATOS
Sector
Primary listing
Employees
16
Headquarters
Website
ATOS Metrics
BasicAdvanced
$41m
-
-$4.37
1.25
-
Price and volume
Market cap
$41m
Beta
1.25
52-week high
$7.56
52-week low
$3.76
Average daily volume
57k
Financial strength
Current ratio
4.917
Quick ratio
4.253
Profitability
EBITDA (TTM)
-39.581
Management effectiveness
Return on assets (TTM)
-45.54%
Return on equity (TTM)
-78.58%
Valuation
Price to book
1.35
Price to tangible book (TTM)
1.35
Price to free cash flow (TTM)
-1.232
Free cash flow yield (TTM)
-81.14%
Free cash flow per share (TTM)
-3.878
Growth
Earnings per share change (TTM)
40.33%
3-year earnings per share growth (CAGR)
9.05%
10-year earnings per share growth (CAGR)
-43.33%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atossa Therapeutics stock?
Atossa Therapeutics (ATOS) has a market cap of $41M as of May 20, 2026.
What is the P/E ratio for Atossa Therapeutics stock?
The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of May 20, 2026.
Does Atossa Therapeutics stock pay dividends?
No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next Atossa Therapeutics dividend payment date?
Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Atossa Therapeutics?
Atossa Therapeutics (ATOS) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.